Salarius Pharmaceuticals shares are trading lower after the company was notified by MD Anderson Cancer Center of a Grade 4 adverse event in the Seclidemstat clinical trial. The FDA has placed the trial on partial clinical hold, preventing new patient enrollment while allowing current patients to continue treatment.
Portfolio Pulse from Benzinga Newsdesk
Salarius Pharmaceuticals shares are trading lower after the company was notified by MD Anderson Cancer Center of a Grade 4 adverse event in the Seclidemstat clinical trial. The FDA has placed the trial on partial clinical hold, preventing new patient enrollment while allowing current patients to continue treatment.
July 18, 2024 | 3:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Salarius Pharmaceuticals shares are trading lower after the company was notified by MD Anderson Cancer Center of a Grade 4 adverse event in the Seclidemstat clinical trial. The FDA has placed the trial on partial clinical hold, preventing new patient enrollment while allowing current patients to continue treatment.
The FDA's decision to place the Seclidemstat trial on partial hold due to a Grade 4 adverse event is a significant regulatory setback for Salarius Pharmaceuticals. This will likely lead to a negative short-term impact on the stock price as it halts new patient enrollment, raising concerns about the drug's safety profile.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100